ADXN Addex Therapeutics Ltd

0.0292USD0.0246 CHF · SWX+0.82%Mkt Cap: 6.14M USDP/E: —

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enz…

Key Statistics

Company
Market Cap6.14M USD
Enterprise Value2.90M USD
Revenue (TTM)98.57K USD
Gross Profit-322.97K USD
Net Income (TTM)-7.98M USD
Revenue/Share0.0012 USD
Last Price0.0292 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0029850754
Valuation
P/E (Trailing)—
P/E (Forward)-0.61
PEG—
EV/EBITDA-0.94
EV/Revenue29.43
P/S62.28
P/B1.64
EPS (TTM)-0.06 USD
EPS (Forward)-0.05 USD
52W Range
0.021413% of range0.0819
52W High0.0819 USD
52W Low0.0214 USD
Profitability
Gross Margin0.00%
Oper. Margin-3130.67%
EBITDA Margin0.00%
Profit Margin-22448.44%
ROE-141.15%
ROA-105.72%
ROIC-89.14%
ROCE-54.49%
Growth
Revenue Growth-72.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.58M USD
CapEx (TTM)—
FCF Margin-1727.66%
FCF Yield-27.74%
Net Debt-818.57K USD
Net Debt/EBITDA0.26
Net Debt/FCF—
Balance Sheet
Debt/Equity0.01
Current Ratio0.76
Quick Ratio0.58
Book Value/Sh0.02 USD
Cash/Share0.0071 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 26, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.210.29M
Float55.89M
Insiders7.08%
Institutions0.81%
Technical
SMA 500.0273 (+6.8%)
SMA 2000.0449 (-35.0%)
Beta2.07
S&P 52W Chg12.00%
Avg Vol (30d)1.69M
Avg Vol (10d)4.42M
Technical Indicators
RSI (14)50.5
MACD0.0011
MACD Signal0.0007
MACD Hist.+0.0004
BB Upper0.0376 USD
BB Middle0.0282 USD
BB Lower0.0187 USD
BB Width67.14%
ATR (14)0.0046 USD
Vol Ratio (20d)0.20x

About Addex Therapeutics (SWX: ADXN)

›

Addex Therapeutics (SWX: ADXN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.

The shares were at 0.0246 CHF on 19 November 2026, down 60.2% over 52 weeks. Its 52-week range is 0.0180 CHF to 0.0690 CHF: the price is 64.3% below the high and 36.7% above the low.

Its market capitalisation is 5.17M CHF.

Addex Therapeutics reports return on equity of -141.2% and revenue down 72.7% year over year.

It holds more cash than debt, a net cash position of 689.83K CHF. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 November 2026.